{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:45:03Z","timestamp":1795088703487,"version":"4.10.2"},"reference-count":16,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T00:00:00Z","timestamp":1122940800000},"content-version":"vor","delay-in-days":2040,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:title>Summary:<\/jats:title><jats:p> <jats:italic>Purpose<\/jats:italic>: Six double\u2010blind, placebo\u2010controlled trials were conducted with topiramate (TPM) initiated as adjunctive therapy in adults with treatment\u2010resistant partial\u2010onset seizures with or without secondary generalization.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>: Because protocols and study populations were similar, data from the studies were pooled and analyzed for 527 patients treated with TPM and 216 treated with placebo.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>: Seizures were reduced 50% in 43% of TPM\u2010treated patients and in 12% of placebo\u2010treated patients (p &lt; 0\u00b7001); 5% of TPM\u2010treated patients, but no placebo\u2010treated patients, were seizure free during 11\u201319 weeks of double\u2010blind treatment (p &lt; 0\u00b7001). The therapeutic effect was consistent regardless of seizure type, age, gender, baseline seizure rate, or concomitant antiepileptic drug (AED). With 100 mg\/day TPM as a starting dosage and weekly dosage increments of 100\u2013200 mg\/day added to maximally tolerated dosages of AEDs, the most common treatment\u2010emergent adverse events (TEAEs) were dizziness, somnolence, fatigue, psychomotor slowing, nervousness, paresthesia, ataxia, memory difficulty and speech problems. These central nervous system effects were generally mild to moderate in severity, usually occurred early in treatment, often during titration, and resolved with continued treatment. Other notable TEAEs were weight loss and, in a small percentage of patients, renal calculi.<\/jats:p>","DOI":"10.1111\/j.1528-1157.2000.tb02175.x","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T06:38:27Z","timestamp":1123051107000},"page":"66-71","source":"Crossref","is-referenced-by-count":122,"title":["Topiramate as Add\u2010On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults"],"prefix":"10.1111","volume":"41","author":[{"given":"Ross","family":"Reife","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Pledger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu\u2010Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1684"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1678"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00029-0"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00649.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00606.x"},{"issue":"5","key":"e_1_2_1_7_2","first-page":"153","article-title":"Topiramate YF\/YG Study Group. Placebo\u2010controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial\u2010onset epilepsy","volume":"37","author":"Rosenfeld W","year":"1996","journal-title":"Epilepsia"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01251.x"},{"key":"e_1_2_1_10_2","first-page":"603","article-title":"Analysis based on number needed to treat shows differences between drugs studied [Letter]","volume":"314","author":"Elferink AJA","year":"1997","journal-title":"Br Med J"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.912"},{"issue":"2","key":"e_1_2_1_12_2","first-page":"A39","article-title":"Topiramate TPS\u2010TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate","volume":"48","author":"Edwards KR","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb04521.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834050-00001"},{"issue":"6","key":"e_1_2_1_15_2","first-page":"55","article-title":"The office use of topiramate: a review of seizure control and side\u2010effect profile","volume":"39","author":"Gogol LM","year":"1998","journal-title":"Epilepsia"},{"issue":"6","key":"e_1_2_1_16_2","first-page":"55","article-title":"Role of topiramate (Topamax) in adults with intractable epilepsy, mental retardation, and developmental disabilities","volume":"39","author":"Singh BK","year":"1998","journal-title":"Epilepsia"},{"issue":"6","key":"e_1_2_1_17_2","first-page":"56","article-title":"Tolerability of topiramate as monotherapy in patients with recently diagnosed partial epilepsy","volume":"39","author":"Gilliam FG.","year":"1998","journal-title":"Epilepsia"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1157.2000.tb02175.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1157.2000.tb02175.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T20:26:50Z","timestamp":1695760010000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.2000.tb02175.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":16,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1111\/j.1528-1157.2000.tb02175.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1157.2000.tb02175.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}